Medco Research, Inc. and Repligen Corporation Have Agreed to Merge

Oncology NEWS International Vol 4 No 7, Volume 4, Issue 7

CAMBRIDGE, Mass--Repligen Corporation and Medco Research, Inc. (Research Triangle Park, NC) have agreed to merge their two companies. The resulting company's product portfolio will serve three primary markets: cardiovascular disease, oncology, and immunology.

CAMBRIDGE, Mass--Repligen Corporation and Medco Research, Inc.(Research Triangle Park, NC) have agreed to merge their two companies.The resulting company's product portfolio will serve three primarymarkets: cardiovascular disease, oncology, and immunology.

Medco's products include ATP, an adenosine product under investigationas an antitumor agent and to prevent the weight loss and wastingassociated with chemotherapy and radiation. Among Repligen's cancerdrugs under development is recombinant platelet factor 4 (rPF4),which has shown potential as an antiangiogenesis agent.